title: Treatment of H. pylori infection: a review.
abstract: Helicobacter pylori infection has been indicated as the main pathogenic factor in the development of chronic gastritis, peptic ulcer disease, and gastric malignancies. Although the vast majority of infected subjects do not carry but a mild, asymptomatic gastritis, still there are some cases in which the eradication of the infection appears mandatory. This review addresses current anti-Helicobacter regimens and pharmacological resources, and highlights the pros and cons of each of them, according to the most recent and reliable clinical trials. Also, basic recommendations are given, regarding treatment choice in the event of the failure of a first or second line eradicating strategy, and about the implementation of standard regimens with newer antibacterial devices as probiotics.
authors.affiliation: Department of Internal Medicine, Catholic University of Rome, Italy.
authors.forename: Marcello
authors.initials: M
authors.lastname: Candelli
authors.forename: Enrico C
authors.initials: EC
authors.lastname: Nista
authors.forename: Emilia
authors.initials: E
authors.lastname: Carloni
authors.forename: Giulia
authors.initials: G
authors.lastname: Pignataro
authors.forename: Maria Assonta
authors.initials: MA
authors.lastname: Zocco
authors.forename: Alossia
authors.initials: A
authors.lastname: Cazzato
authors.forename: Cristiana
authors.initials: C
authors.lastname: Di Campli
authors.forename: Lucia
authors.initials: L
authors.lastname: Fini
authors.forename: Giovanni
authors.initials: G
authors.lastname: Gasbarrini
authors.forename: Antonio
authors.initials: A
authors.lastname: Gasbarrini
mesh_terms: D000658:Amoxicillin / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001729:Bismuth / Q000737:chemistry / Q000494:pharmacology; D017291:Clarithromycin / Q000737:chemistry / Q000494:pharmacology; D024841:Fluoroquinolones / Q000494:pharmacology; D005664:Furazolidone / Q000494:pharmacology; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000472:pathogenicity; D006801:Humans; D018942:Macrolides / Q000494:pharmacology; D015242:Ofloxacin / Q000494:pharmacology; D019338:Polypharmacy; D011899:Ranitidine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D017828:Rifabutin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D018942:Macrolides; D017828:Rifabutin; D005664:Furazolidone; C073340:ranitidine bismuth citrate; D000658:Amoxicillin; D011899:Ranitidine; D015242:Ofloxacin; D017291:Clarithromycin; D001729:Bismuth